These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 28837942)

  • 1. Obsessive-compulsive disorder presenting with gender incongruence obsessions.
    Uvais NA; Sreeraj VS
    Asian J Psychiatr; 2017 Dec; 30():77-78. PubMed ID: 28837942
    [No Abstract]   [Full Text] [Related]  

  • 2. Psychopharmacology of pediatric obsessive-compulsive disorder: three case reports.
    Oner O; Oner P
    J Psychopharmacol; 2008 Sep; 22(7):809-11. PubMed ID: 18308783
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risperidone and haloperidol augmentation of serotonin reuptake inhibitors in refractory obsessive-compulsive disorder: a crossover study.
    Li X; May RS; Tolbert LC; Jackson WT; Flournoy JM; Baxter LR
    J Clin Psychiatry; 2005 Jun; 66(6):736-43. PubMed ID: 15960567
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antiobsessional effect of risperidone add-on treatment in serotonin reuptake inhibitor-refractory obsessive-compulsive disorder may be dose-dependent.
    Ramasubbu R
    Arch Gen Psychiatry; 2002 May; 59(5):472; author reply 472-3. PubMed ID: 11982460
    [No Abstract]   [Full Text] [Related]  

  • 5. Obsessive-compulsive symptoms in schizophrenia induced by risperidone and responding to fluoxetine.
    Levy E; Margolese HC; Sultan S; Chouinard G
    Can J Psychiatry; 2003 Nov; 48(10):709-10. PubMed ID: 14674056
    [No Abstract]   [Full Text] [Related]  

  • 6. Risperidone augmentation of paroxetine in a case of severe, treatment-refractory obsessive-compulsive disorder without comorbid psychopathology.
    Agid O; Lerer B
    J Clin Psychiatry; 1999 Jan; 60(1):55-6. PubMed ID: 10074882
    [No Abstract]   [Full Text] [Related]  

  • 7. Comment on adult baby syndrome.
    Croarkin P; Nam T; Waldrep D
    Am J Psychiatry; 2004 Nov; 161(11):2141; author reply 2142. PubMed ID: 15514436
    [No Abstract]   [Full Text] [Related]  

  • 8. The use of sumatriptan in the treatment of obsessive-compulsive disorder in an adolescent.
    Pathak S; Cottingham EM; McConville BJ
    J Child Adolesc Psychopharmacol; 2003; 13 Suppl 1():S93-4. PubMed ID: 12880505
    [No Abstract]   [Full Text] [Related]  

  • 9. Augmenting obsessive-compulsive disorder treatment: from brain to mind.
    Ressler KJ; Rothbaum BO
    JAMA Psychiatry; 2013 Nov; 70(11):1129-31. PubMed ID: 24026506
    [No Abstract]   [Full Text] [Related]  

  • 10. [The mental disorder and obsessive-compulsive spectrum disorders in childhood ].
    Okada T
    Seishin Shinkeigaku Zasshi; 2011; 113(10):992-8. PubMed ID: 22292193
    [No Abstract]   [Full Text] [Related]  

  • 11. The comparison of aripiprazole and risperidone augmentation in selective serotonin reuptake inhibitor-refractory obsessive-compulsive disorder: a single-blind, randomised study.
    Selvi Y; Atli A; Aydin A; Besiroglu L; Ozdemir P; Ozdemir O
    Hum Psychopharmacol; 2011 Jan; 26(1):51-7. PubMed ID: 21308781
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Olanzapine addition in obsessive-compulsive disorder refractory to selective serotonin reuptake inhibitors: an open-label case series.
    Weiss EL; Potenza MN; McDougle CJ; Epperson CN
    J Clin Psychiatry; 1999 Aug; 60(8):524-7. PubMed ID: 10485634
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risperidone augmentation of serotonin reuptake inhibitors in obsessive-compulsive and related disorders.
    Stein DJ; Bouwer C; Hawkridge S; Emsley RA
    J Clin Psychiatry; 1997 Mar; 58(3):119-22. PubMed ID: 9108814
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Delayed obsessive-compulsive disorder symptom exacerbation after a single dose of a serotonin antagonist in fluoxetine-treated but not untreated patients.
    Greenberg BD; Benjamin J; Martin JD; Keuler D; Huang SJ; Altemus M; Murphy DL
    Psychopharmacology (Berl); 1998 Dec; 140(4):434-44. PubMed ID: 9888619
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of factor-analyzed symptom dimensions to predict outcome with serotonin reuptake inhibitors and placebo in the treatment of obsessive-compulsive disorder.
    Mataix-Cols D; Rauch SL; Manzo PA; Jenike MA; Baer L
    Am J Psychiatry; 1999 Sep; 156(9):1409-16. PubMed ID: 10484953
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of fluoxetine in preschool children with obsessive-compulsive disorder.
    Coskun M; Zoroglu S
    J Child Adolesc Psychopharmacol; 2009 Jun; 19(3):297-300. PubMed ID: 19519265
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Obsessive-compulsive symptoms with risperidone.
    Mahendran R
    J Clin Psychiatry; 1999 Apr; 60(4):261-3. PubMed ID: 10221290
    [No Abstract]   [Full Text] [Related]  

  • 18. Aripiprazole augmentation in 13 patients with refractory obsessive-compulsive disorder: a case series.
    Higuma H; Kanehisa M; Maruyama Y; Ishitobi Y; Tanaka Y; Tsuru J; Hanada H; Kodama K; Isogawa K; Akiyoshi J
    World J Biol Psychiatry; 2012 Jan; 13(1):14-21. PubMed ID: 22256827
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A double-blind, placebo-controlled study of risperidone addition in serotonin reuptake inhibitor-refractory obsessive-compulsive disorder.
    McDougle CJ; Epperson CN; Pelton GH; Wasylink S; Price LH
    Arch Gen Psychiatry; 2000 Aug; 57(8):794-801. PubMed ID: 10920469
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of selective serotonin reuptake inhibitors on thought-action fusion, metacognitions, and thought suppression in obsessive-compulsive disorder.
    Besiroglu L; Çetinkaya N; Selvi Y; Atli A
    Compr Psychiatry; 2011; 52(5):556-61. PubMed ID: 21109243
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.